{"ticker": {"uuid": "4434bb49-ff36-4457-920e-6c23e0b7b742", "symbol": "VCYT", "name": "Veracyte Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "A Look at Veracyte Inc (VCYT) After 5.1% Gain -- GF Value $38.30 vs Price $59.51", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOcUdPOEpKLTRPeFdwS3NqWDgwNzh5Q2ZCQ19QbU5CZnV0LVYydm1hU0lkZWkwZlFVNWFqRmpSc2JsbkYxQ2pLZHRwMnk4QmZBMDZkUGVZejJ1SUVjREMzWDdPMlJCSTZGa183QTYxUHhFbl9ySm1SNlo0TjNHaE9hbmVEU0dFckxnVEhuOWtDWlZ2UmlEVlJvSERGTENCVkdrUGlyQy1FUklfaUR3X0tlclFkTmt5UkRGaHRrSg?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T23:23:47+00:00", "published_display": "15 Jul 2026 23:23", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler initiates Veracyte stock with overweight rating", "summary": "Piper Sandler has initiated coverage on Veracyte (NASDAQ:VCYT) with an overweight rating and a price target of $66.00, citing the company's cash-generative diagnostics lab anchored by its Afirma and Decipher Prostate genomic classifiers. These products are expected to drive signi", "url": "https://m.uk.investing.com/news/stock-market-news/piper-sandler-initiates-veracyte-stock-with-overweight-rating-93CH-4771072?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-15T21:40:59", "published_display": "15 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Initiates Veracyte at Overweight With $66 Price Target", "summary": "Piper Sandler has initiated coverage on Veracyte (NASDAQ: VCYT) with an Overweight rating and set a price target of $66. This news comes as Veracyte continues to expand its diagnostic test offerings for various cancers and respiratory diseases. The company was also recently added", "url": "https://www.marketscreener.com/news/piper-sandler-initiates-veracyte-at-overweight-with-66-price-target-ce7f5ed2d989f42c", "source_name": "www.marketscreener.com", "published_at": "2026-07-15T12:40:59", "published_display": "15 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxNT2J0QlhoWjJlTWlMQzFlUTBQdmtBVjFBT3lrRnc1VWhEVWVDMklvRVlFTFVKMHJxMVhuNEQ5blNob3paSC1HZFdWd05Jc2d4NVBaa0JOaU1UWHBBVWNGc2ZIUU0yU1JGb1FhYVRvUUhDa3NyVDJPRTYwdE5nd1dMTGJZOEJVbUx1c1A5NzlzSHVWOFoxa18wQ096RW1MMUpGOXMyaW9lNmIzemR4QzcxQkdtYm5tS3lpcmw5WjZWQno3RURWaXQwWDVZRDhVazY0NWpMQkZMRmtyNndHcUVpSkRsV184SmxFV29HeXRJRGtqaXRFWUNXQjA2SlJqUQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-15T10:59:53+00:00", "published_display": "15 Jul 2026 10:59", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VCYT Initiated Coverage by Piper Sandler -- Rating Overweight", "summary": "Piper Sandler has initiated coverage on Veracyte (VCYT) with an Overweight rating and a price target of $66.00, reflecting a positive outlook on the genomic diagnostics company. However, GuruFocus indicates that VCYT is significantly overvalued by 47.8% compared to its intrinsic ", "url": "https://www.gurufocus.com/news/8959534/vcyt-initiated-coverage-by-piper-sandler-rating-overweight?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T10:12:57", "published_display": "15 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Raises Target Price to $60", "summary": "CCORF has reiterated its Hold rating on Veracyte (VCYT.US) while increasing the target price to $60. This adjustment reflects a continued cautious but not negative outlook on the company's stock performance.", "url": "https://www.moomoo.com/news/post/72937094/ccorf-maintains-veracyte-vcytus-with-hold-rating-raises-target-price", "source_name": "Moomoo", "published_at": "2026-07-15T00:12:57", "published_display": "15 Jul 2026 00:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026", "summary": "Veracyte, Inc. (NASDAQ: VCYT) announced it will release its second quarter 2026 financial results on Wednesday, July 30, 2026, after the close of market. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results and provide a busin", "url": "https://www.moomoo.com/news/post/72736095/press-release-veracyte-to-release-second-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-07-10T11:10:55", "published_display": "10 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Maintains Veracyte(VCYT.US) With Sell Rating, Raises Target Price to $47", "summary": "Morgan Stanley has reiterated its Sell rating on Veracyte (VCYT.US) but decided to raise its target price for the stock to $47. This indicates a continued bearish outlook despite a potentially improved valuation.", "url": "https://www.moomoo.com/news/post/72723676/morgan-stanley-maintains-veracyte-vcytus-with-sell-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-07-10T08:40:06", "published_display": "10 Jul 2026 08:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veracyte-release-second-quarter-2026-200500108.html", "source_name": "Business Wire", "published_at": "2026-07-09T20:05:00+00:00", "published_display": "09 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte sets July 30 call for Q2 2026 results and update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNTnZsZkRCcEZ1dkp4Y0tYeExCZFlDWG1mc0k3YTNXZ2lSZjJXTkswUGo5VWMybWN6YnpyTm5pbXYzZDR2VEJxZUlhX19ROGE2SW9YV0pOMUZBMzYzN3lPeGVhYy0yWlZhT05jRUJRZkdEdldNTGlaX3RvVk1CY2xRZjA0Y2R3R2JISjN1R1V5T0tQN2xkU2l4QXB2a1hBRVMtSU5MWGNGLS1mOXd1R2hWMmMzaTduSVhoRGNfOG5CV1I?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T20:05:00+00:00", "published_display": "09 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VCYT Maintained by Morgan Stanley -- Price Target Raised to $47.", "summary": "Morgan Stanley has maintained an \"underweight\" rating on Veracyte (VCYT) despite raising its price target to $47. The stock is currently trading 53.9% above its GF Value\u2122 of $38.24, indicating it is overvalued. While VCYT has a strong GF Score\u2122 of 75, driven by financial strength", "url": "https://www.gurufocus.com/news/8952082/vcyt-maintained-by-morgan-stanley-price-target-raised-to-4700", "source_name": "GuruFocus", "published_at": "2026-07-09T18:15:46", "published_display": "09 Jul 2026 18:15", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc. Stock 12\u2011Month Price Target Raised to $55.8, Implies 1% Downside", "summary": "Veracyte, Inc.'s average 12-month stock price target has been increased from $54.8 to $55.8 by 10 analysts, with individual forecasts ranging from $42 to $70 per share. Based on the July 8 closing price, this new target suggests a potential 1% downside. The consensus rating from ", "url": "https://www.tradingview.com/news/tradingview:dda31ed86064b:0-veracyte-inc-stock-12-month-price-target-raised-to-55-8-implies-1-downside/", "source_name": "TradingView", "published_at": "2026-07-09T13:15:45", "published_display": "09 Jul 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Veracyte\u2019s (VCYT) Russell Value Index Debut Redefine Its Small-Cap Defensive Narrative?", "summary": "Veracyte (VCYT) was recently included in several Russell value and defensive indices, including the Russell 3000 Value and Russell 2000 Value-Defensive. While these inclusions may attract short-term investor interest and highlight a reclassification of the company, the core inves", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/does-veracytes-vcyt-russell-value-index-debut-redefine-its-s", "source_name": "Simply Wall Street", "published_at": "2026-07-09T06:40:41", "published_display": "09 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Inc updates investors on breast cancer test coverage. Nasdaq-listed diagnostics group builds on genomic portfolio", "summary": "Veracyte Inc is highlighting expanded Medicare coverage for its Prosigna breast cancer assay, a genomic test used to assess recurrence risk. This expansion is crucial for investors as Medicare decisions often influence other payers, potentially increasing test volumes and strengt", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/veracyte-inc-updates-investors-on-breast-cancer-test-coverage/69725654", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T17:39:40", "published_display": "08 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNM0Flb1MzbmVDNGZXRmRZMDA3NW5oRzYzem43T2dzdmtfX3EtZTU0QlplanJOeFBkaDdOaGt5QlVCWWE0VHlQYURpSnBESTZzUDViSEUwempiWjVsbzZVd0pxS2cxYms3Q0RBd0hzWDVYbkRkRHJXVThqR3lCMUVSTVphOWVsNEdLMDBocUo5SU5fUWdMam1YMFdUNVBIWjA?oc=5", "source_name": "Market source", "published_at": "2026-07-08T16:00:04+00:00", "published_display": "08 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Veracyte (VCYT) Fully Valued As Insider Selling And Index Additions Draw Attention?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Inc (VCYT) Stock Down 3.2% but Still Overvalued -- GF S", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAJBVV95cUxPcENKT0twTmJfSXI3cWcxY2piTzBsam1sM1dkdG84ZWZETXc0RnZVV0V5VFpyOXV4ZGttMmJiTUMzRnZoWUNibHp2c3B3X2RGNEhOQmV0UXdoZkdMaG1RYXNZQ0dJcEY4SHpjN0VWVXp2SHRSRTlVdUhyU2dMc09WY0NOZ2M2YVZrcjhmV0pWVm8zY05Yb2Y1WlBxQXRQSzhKOTZoUEZlQlM4d3lMckQwaFJpNV9raWdqamdzTjdIUE0yY0s5Mm1YekN1cG5vbzRiWVJXb1ZqcXlQNi1SQ1oyRTYybFFfcmtOaXgzTFk1M19ScG1TYVdzYm5zTTdXNmRzTElWWk9Gdm1UVjhaWktCZjI0cVZZZWVqYmJVZGw1a3M2TWIyV05naThxR21QZl9PbmgwN25xbGNhdU1DdVFQdnNySm9pcXRDeWdXOA?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.", "summary": "Veracyte's Chief Accounting Officer, Jonathan Wygant, sold 24,000 shares for $1.1 million after exercising options, reducing his direct ownership by 34.57%. This transaction, along with a subsequent smaller sale, capitalized on the company's rising stock price driven by strong Q1", "url": "https://finance.yahoo.com/markets/stocks/articles/veracyte-insider-sold-24-000-132501389.html", "source_name": "Market source", "published_at": "2026-07-04T13:40:54", "published_display": "04 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Inc (VCYT) Stock Forecast, Price Targets and Analysts Predictions", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gJBVV95cUxOTXZWU2d4UEJwdVdPeEs2SmttODVOdHdqT0xHckwtNkJla2cxeENNNGVCZEhyRHBzNTFIaHBSRUtNUmZ3YjZNSGRqcVJMWmowajlBN2hZdE91cDNjVjFMTjF1WVFVaUVMeEpNUXNOSXJZUTBXNWlJN0wxRVZJLU5Bd0JvekRHd2hwbFA3WGxWb2ZlWm16SS1RSjZWZUhmZEVyUWxBM2RQUFc3dzNNWnR0VnhwVk00RWxTU2FLUldHdWFuYTlzWTBhRkdSRC1hdWcxWm8zc3hLeGJTb0VxLVpraG9rb1pyZlVCUEE2YmJIODRJcTY1RFMyRlh3QlgzOFF2VUlQOUZnTGFFNWo0R0tQVzVDWmFIQWtBZGZjdlVrTG1RR0YtRzA2ei1VTVNERGVZaFNvZ3JIb2VRZlZ3VkNsUms2LWNBamJmYUtMdnNBMld5eUNHME1KWDJR?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-03T14:14:28+00:00", "published_display": "03 Jul 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Stock Surges 117% in a Year: What's Driving the Rally?", "summary": "Veracyte's stock has surged 117% over the past year, significantly outperforming its industry and the S&P 500, driven by its long-term growth strategy focusing on minimal residual disease testing, international expansion, and new product development. Key catalysts include strong ", "url": "https://www.tradingview.com/news/zacks:74b44e756094b:0-veracyte-stock-surges-117-in-a-year-what-s-driving-the-rally/", "source_name": "TradingView", "published_at": "2026-07-02T18:12:20", "published_display": "02 Jul 2026 18:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 3000 Value Benchmark", "summary": "Veracyte, Inc. (NasdaqGM: VCYT), a global diagnostics company, has been added to the Russell 3000 Value Benchmark. This news follows several other recent additions to various Russell indices, including the Russell 2000 Value, Russell 2000 Value-Defensive, and Russell 3000E Value ", "url": "https://www.marketscreener.com/news/veracyte-inc-nasdaqgm-vcyt-added-to-russell-3000-value-benchmark-ce7f5fdcd08af027", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:39:31", "published_display": "29 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2500 Value Benchmark", "summary": "Veracyte, Inc. (VCYT) has been added to the Russell 2500 Value Benchmark, as well as several other Russell indices including the Russell 2000 Value Benchmark, Russell 2000 Value-Defensive Index, and Russell 3000 Value Benchmark. This inclusion signifies the company's recognition ", "url": "https://www.marketscreener.com/news/veracyte-inc-nasdaqgm-vcyt-added-to-russell-2500-value-benchmark-ce7f5fdfde89f727", "source_name": "marketscreener.com", "published_at": "2026-06-29T19:39:50", "published_display": "29 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VCYT Maintained by Guggenheim -- Price Target Raised to $65", "summary": "Guggenheim maintained a \"Buy\" rating for Veracyte (VCYT) and significantly increased its price target from $45.00 to $65.00, reflecting confidence in the company's future growth. Despite this positive analyst outlook and a strong GF Score\u2122 of 75/100, GuruFocus indicates VCYT is 5", "url": "https://www.gurufocus.com/news/8936431/vcyt-maintained-by-guggenheim-price-target-raised-to-65", "source_name": "GuruFocus", "published_at": "2026-06-29T15:41:50", "published_display": "29 Jun 2026 15:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) Enters Multiple Russell Indexes Is Its Small-Cap Profile Quietly Changing?", "summary": "Veracyte (VCYT) has been added to several Russell indexes, including the Russell 2000 Defensive and Growth-Defensive, which could significantly increase its institutional investor base and trading liquidity. While this inclusion may boost awareness for the company's cancer diagno", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracyte-vcyt-enters-multiple-russell-indexes-is-its-small-c", "source_name": "Simply Wall Street", "published_at": "2026-06-29T14:41:50", "published_display": "29 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Veracyte, Inc. \u2013 NASDAQ:VCYT", "summary": "This page from TradingView displays financial data for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its Price to Book Forward metric. The content lists various financial tools and market data services provided by TradingView and its partners.", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:41:50", "published_display": "29 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2000 Value-Defensive Index", "summary": "Veracyte, Inc. (NasdaqGM: VCYT), a global diagnostics company, has been added to the Russell 2000 Value-Defensive Index. The company provides various diagnostic tests for cancers previously mentioned in the article, such as thyroid cancer and breast cancer, and is developing test", "url": "https://www.marketscreener.com/news/veracyte-inc-nasdaqgm-vcyt-added-to-russell-2000-value-defensive-index-ce7f5fdedb8dfe2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T22:42:00", "published_display": "28 Jun 2026 22:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Veracyte, Inc. \u2013 FWB:12V", "summary": "This article provides financial information for Veracyte, Inc. (FWB:12V) on TradingView, specifically focusing on its enterprise value to revenue forward. It indicates the market status as closed with no trades, and the content primarily consists of navigation and boilerplate inf", "url": "https://www.tradingview.com/symbols/FWB-12V/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T19:39:50", "published_display": "28 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Veracyte, Inc. \u2013 FWB:12V", "summary": "This article provides financial information for Veracyte, Inc. (FWB:12V), specifically focusing on its price-to-sales forward metric. The data is sourced from exchanges and financial data providers, indicating that the market for this stock was closed with no trades recorded at t", "url": "https://www.tradingview.com/symbols/FWB-12V/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:41:50", "published_display": "28 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Veracyte, Inc. \u2013 NASDAQ:VCYT", "summary": "This page provides financial information for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its forward price-to-sales ratio. The content appears to be a financial data page from TradingView, offering an overview of the company's financials for investors and analysts. It", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:40:03", "published_display": "28 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Veracyte, Inc. \u2013 NASDAQ:VCYT", "summary": "This article provides financial information for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its enterprise value to EBIT forward. The content is presented within the TradingView platform, which offers various financial tools and data.", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T11:11:16", "published_display": "28 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Veracyte, Inc. \u2013 FWB:12V", "summary": "This article provides financial information for Veracyte, Inc. (FWB:12V), focusing on its forward price-to-earnings ratio. It states that the market is currently closed with no trades recorded and offers data made by humans from various financial services.", "url": "https://www.tradingview.com/symbols/FWB-12V/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:10:34", "published_display": "28 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Veracyte, Inc. \u2013 NASDAQ:VCYT", "summary": "This article provides a brief snapshot of the \"Enterprise value to EBITDA forward\" for Veracyte, Inc. (NASDAQ: VCYT) according to TradingView. It indicates that the market was closed at the time the data was viewed, with no trades recorded. The content is primarily a data point w", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:10:34", "published_display": "27 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) On Pipeline Momentum And A Valuation Question", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-27T09:20:06+00:00", "published_display": "27 Jun 2026 09:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQSXBZeVBPc05Rd0JaczBwTGNaMGN0N2Jnc3F1MktVRzdwLVhPWWFadks0Q2lIYkZJQVM2TFFPZlI1dkZfVkFnTzNReHg0WWdFN0U4d3BwYnZ2cVNDVnlBa0NYektwdHd3RS1JVXZLaDBQNG9wQkw0dzVvWjhkVDdRRENHRl80SlBrS1lZRmY3aVZqRGsxMGs2aURLQU5TdXVOLUQxWWd4Q2VXRThxU0hTUE9wVFdJZmw3Znhsek9lcjMyQUUtaTAwUktR?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc. Actuals & Estimates (NASDAQ:VCYT)", "summary": "This article provides an overview of Veracyte, Inc. (NASDAQ: VCYT) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, such as recent earnings, revenue, net income, and market capitaliza", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T06:10:34", "published_display": "27 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc. Actuals & Estimates (MUN:12V)", "summary": "This article provides an overview of Veracyte, Inc. (MUN:12V) financials, analyst estimates, and key company data. It includes details on past earnings performance, revenue, EBITDA, and analyst price targets, alongside upcoming earnings report dates. The article also addresses fr", "url": "https://www.tradingview.com/symbols/MUN-12V/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T05:39:56", "published_display": "27 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc. Actuals & Estimates (DUS:12V)", "summary": "This article provides an overview of Veracyte, Inc. (12V) stock details, including financial actuals, analyst estimates, and key performance indicators. It covers income statements, balance sheets, cash flow, and valuation metrics, along with answers to frequently asked questions", "url": "https://www.tradingview.com/symbols/DUS-12V/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T03:11:36", "published_display": "27 Jun 2026 03:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Inc (VCYT) Shares Surge 3.1% -- What GF Score of 75 Tell Investors", "summary": "Veracyte Inc (VCYT) shares surged 3.1% to $58.59 on June 25, 2026, marking a 30.0% appreciation over the last month. Despite a strong GF Score of 75/100, indicating above-average performance, the stock is considered \"Significantly Overvalued\" with a current price considerably abo", "url": "https://www.gurufocus.com/news/8932818/veracyte-inc-vcyt-shares-surge-31-what-gf-score-of-75-tells-investors?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-26T06:10:34", "published_display": "26 Jun 2026 06:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VCYT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Veracyte, Inc. (VCYT) stock, based on analyst ratings and current market performance. It details the company's financial metrics, including recent earnings and revenue, and answers frequently asked questions about its stock pe", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:02", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte stock hits 52-week high at 55.32 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOWGlMZFNxWDBXQV9IOHdDVWJ1cjZyTXlDTEhkbmMxYjJ4ZkRjcFpXSGNKUjd1MjZPN3ZaeWkxWXZmNVlnRk9BbUFvbnlGNnlPdktfREN5S1B2OWtzN1FDeG5ibTdFOTVhd3hMVTRpd0J5UUhOaEFnOUdVaUZLQVdpYzRDQml1YTdkTzZLU1hNVk10UmM5Q2VvbHFTTDBybXl5TFE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) director logs 3,729-share Rule 10b5-1 stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQREhtVGloQk0zRUk5UnpKWXVDUk5USE1fbFRzeWlfbGxicnd4VWxpZGdJdXE5MVhUOFdGLWVZUEVTb01mNWpWc2tXa084RndpbVUtaGljMEdCc1luekVDamFKdFVvY1pTRHl3Tmw3MmNIR2kyZDZwYW9lOW9jcUJFR1JidjRXTloza1RkblF1bVZsaVJWa05OTC10cWZXNWlpbVdPbjUxTDkwQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Top Stock Has Surged. CEO Explains Key To Veracyte's Success.", "summary": "", "url": "https://finance.yahoo.com/m/b5ac36cb-63db-381e-9915-d11885036996/this-top-stock-has-surged..html", "source_name": "Investor's Business Daily", "published_at": "2026-06-18T20:08:24+00:00", "published_display": "18 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] VERACYTE, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQRGxyaWZXdG1RT3ZIMWtOV2R1RGJxcW50dUlYNWg3MFZlMU5JdFFjNVctdDIzVEJtRHZ2bnhRQXM5ZE5Mdk9ZS1NzcXlpcHEyZWRyUWZlVG5HcnBteUFqZDBnbVpzUlgyUnlUWFQwOUh6d2V4RkVnUzJzam9wTGhZUXV1OEpOaERMU01FcTNRamZzdDg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte CEO Explains How It's Blazing A Trail In Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTFJ2RWFyR3RHWTJXaGFUeGxqMEU1Z0pBUDJPUzVEZGNENnFHQmhmeHQxMzc1T25HbXI4UzFORjlYUGFqQ1c1eWJadkh0dXhwbkhISkt2eEVfTzNLRWp6bTR0dmRXT3FuMGhMWngzSTBEVC01MW4xZGdoaFI4TEtwSmN4bWg3Y01PX2lSd3VmT2oxTjZ0REQ0aFhHaUpPOWZ1OGhjaENCZF8?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQY3I3LUtfZ3d5YkxLb1dvVlRrZUkwWmlCdWFGWTFLcDgyTDdlTzd5TjEycHIxYk5RakJreTJHaGFqSHhEckg4N2E5eW90WDYwek9maGFIcFVuS1NSMmRubjlybWVOeUt3UWJ6YUhhNUV3dml5cWFnNy11RTBVNHpEQ21wM25wWUFUQWEwM013QXZCVFlHZGtnVWRLU18yQlpFcEIyVU05YXpSZWNaS1lvMw?oc=5", "source_name": "ChartMill", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Veracyte (VCYT) receives grant of 5,272 restricted stock units", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQV0NudkxndHR1a085TkhTUUFTZl95X1J2aDN3Znd0SGNubUdmdGNrSEJLdjh2eC1VWUdyM2xsc0hUUDlUeWlKdXh6RVdGc1N4di1QUE9zekFQdm1DWG1nWHpacjJmSnBhSlBwQktzR1R1a2tTTm5WRE5FeF9aNW12VE9hdmI0T09ZY2wtZEFReFRESVFPRHF0TVFaTHF6QmFxV3BGUHRLczdHdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPbWlBeXdKT2NQUnFTMTA4c1R2R1NINXpHRDV3X1UycDJtZkRLN2c2Qm02YWhqa3ZtbFNuN00tQ2gzcmdtV1gzcGg5YzExYnYyTjFzU2lhZkc2VUZ3LVdIYTRHODdkNXo4bTcyWENiNTEtc3YzRWV1TW1jNHM5b2J1bVlSYXNFTmxLWmJYQWRNZE5qbDBPRXM1UEZsQjdrYThSU2c?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQdnpWQ0U1R01DZi1neFkwZ054di1RRVZKMjg5dTdBdjQ2ZXRmZ09JT1FCTTJRRU40a3hQRXVRTWFYeXp0QUltN3hOTUhpdjIzYjlndkJlcl84bGZLV1JOVE5IdHVod0lCY0hSdlNDMGhtNE82NDcwWkxGVWM2bGdtWTMyUldCenh1T0JpYjg4VUE?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOd0FtQU5NZFZQS3pHTzBiYTk5MFZqVEE3UHdRWWxZbU5oclN4ZVRYVkVXLWlKdFlvcTBJcGcxXzB0MDZCV1pHZzR5QU9lQnJMWm9xNndCUlF4ZDZCZGhqZEc0a3lFM2hCa0pXWGVDVjZmTVdHUXdSRHB5SDlEYmU1dUN0NW5leXRLbmRLV2tEWDdVdHJDU3daVWpKSng5dTQ4dV9felBBbUh5SnpxU3RNdVg2UVA0b2pWSEZtNUdyZkdQS24tSlNVQlBRY2FoUQ?oc=5", "source_name": "Business Wire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNdnl4SENLa3I4cXVnMmpsXzFjUEduYWVnODllNXI1Y2tzenptbERZQWlvYUZYVUZ6QjBERDBFRkliMmZGbzItWHEzUm9RdWx5RW9GanY2NHBCblVYUXc5R0IxUlhqZGFfOFlvQWpnZXl0aW1sQjhqY1hQbHhOTFdFTU1URmFDRWhDaGcyb0xxRFczeWlXTl9FZk1IcTN6TFNXejBxS3JqSDNaYmJ4OEVZalowQTdQdzd5?oc=5", "source_name": "TradingView", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOeVE4enVvYlZSWFZvNVNuSzhQdXNSQmxLTkJsZlN1YUdLQ09EenhzOVBnM185WGpfVmh3LVg0SVVwS1BjdFR1TDVXX3l4TWtIS09HU3ZzYm8zZHZFNVpLeDBLamUtWXhzNzRmLXc2dkp6UW0wMHJicldlaFNwbV9BVUUtbmprV05sOVlUaDl2YnJwYkFMMW91RnJn?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Veracyte (VCYT) Valuation After Phase III Success For Prosigna And Decipher Cancer Tests", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMnNHZWh0T1RmT0d6VHNrb3JkbWl3UjRqSXR3Q29ENW5CVDhIMG5uOXRoM3kxWEtoa1p3YVhadGtQNURRQjZsMmp5Qy1XbTNkak1KM0tSdzFOSU9tZjdzamZjak03c0dZWWNqX0NIS3FvWm9GWnFZRVBzdlhNZU54bUVmVGhEMW1FWW1hNFZzRXFsTnF0ZnpCMExLQ2dBUVg4V2g5NFp3Zw?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPNlY5c1FtZ3doN2YyMm1XQnlQRkJnM1lQZ05LdkZXMnBKUDlSaWJReWNGd0hON19qX3daLUxNVnJPNmI2WGZnMFpDQWxpOFN1QXdmUXc2WjVwTDBYYklncHBxUHhuV3hEdEdRZ0hIaWQzQnU5R2tlYzJQTldKVVIwMGttbEtaV0h1dUluR2FBQzF2aHZMSXp3UVg0Ukw5LTFCa0tZNlVsZFI2eTVqZDFhdk1pb2FHS1Q1RWtOQ2lpN0pyTGVCdHdUUVc2RHc3aGpUWElHZU4xV2I2d9IB3wFBVV95cUxOUGdyRWpSWU01WHMyc3haNFdRVDFIZVhpc1pseV9YUTEzLWY0MzFnV1FpWExEd3RTejMweHVBSE11YW1QdGxEcHkzSnpHd0ZhZDR5S2duT2NwdVFweHRFNENWRzdDbHBOeEZMNlJzam0zMUdOcXpWdWZhQkZvZTd0WVJfM2RHdmh4Mmh1MEN1WUdRdmZmRUxBSUNLRHRRTTZnWktLa09JOVh3dWZSZV80dVdxMDJqS2hkemVTN3ZLZ2JmRkRkdU9sczktY3hXYUpfcTNpV3lhWC10YTJ3bmhV?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) Q1 2026 Earnings: Revenue Up 21%, EPS Quadruples, Shares Climb 23% - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNRFRnb1lKY3IyUnhQclM3M3pXaFVKSlV0Z1BYMGp1WUdoOVNZdngtNHFkTlhLbkJlSWtMY3pqaXR5U3NYYVdIZXhIazFZNGJBaFR2RlYzR25pS0JnbGlIcV9vVVBuUk1mUzFVejR5WXM0QTR3MTN1d0QxZGw2UG1udVAwN0xSTzRoWlVSbktpXzVraF9yWEJoaU41MDU5SC1GbWRzelJaSldFZw?oc=5", "source_name": "IndexBox", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) Margin Expansion And 166% Earnings Growth Test Premium Valuation Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPb21JY2wweXFMMW9QeWpCdmlJYWJWTFhSYlh1dWcwQXBvSk8yaGVpNURIRTVkLVN4TTFON25ZMHZEOEstOXRPaXRHZEtaeG5PX2FtUGY2T2QyZmZfN3F5bTZoelJpb2w1aWxGLVdaTDZtZ3ZLd0pEM0x5ejFyWVVMemZwZU03UUhRUFByQmZtVWhIQmU3dzZxMkh4RmRJMDl0Vmc?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZ1p4dmlaYVdiQ1oxa2Y0amFTaFBuTnB0Sms2eDhqY3k1TkZ0SDQ1anVreElaME5BSUMxTFc4TEhxeDJSd1ZDN1lQVzJCNTVXbG13Q0RGLTNJR3dMZXJCd2Jlc0ZKZWJjRXgyWXNjc3FhZEdmbWhDQUZpM0tuNFgzMk8xX2p2Y2dSZ0I0ZU9JZlBTVzlmMWFQeV9wbUU?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Veracyte Stock the Right Pick for Your Portfolio Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQWmFfTjk3QTNfY1FEQ1l6ZU5qWHdUU3pZS2JMNzdpSXNSM0pnLVpyZkZkM2YxX1JiclEwampKSGtXM2diWjE4d2JJejhuX2U3LXRmbzJWREc0OE5tdE5PZjNyNmhkdEFmQUJMRjE0aHdXQTNuek5qSDB2WGFjenpwX2VZUEU3eHJlUUJaVDNUZXZUMVVrRFlIYmRFOUpneUk?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQakNsVVNhVFg2NWZjWXNhWkJGdmZjd2Jlb3owUUkzTFJfdGd0em1QRWxPYWRtT3ozMmg4TXA5TjRLZUJEZkJTRTFsRUJGRk5kaE1OcHpkRlVpV2xqVktLdU5SVUliMnhiZjlxNE9lQzN2OFBKeElWRC1tSmdUMjc5Y3AtSTktV0VLbVp6RXJwN1Vidw?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Taps Kevin Haas To Guide AI Push And Undervalued Shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "A Look at Veracyte Inc (VCYT) After 5.1% Gain -- GF Value $38.30 vs Price $59.51", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOcUdPOEpKLTRPeFdwS3NqWDgwNzh5Q2ZCQ19QbU5CZnV0LVYydm1hU0lkZWkwZlFVNWFqRmpSc2JsbkYxQ2pLZHRwMnk4QmZBMDZkUGVZejJ1SUVjREMzWDdPMlJCSTZGa183QTYxUHhFbl9ySm1SNlo0TjNHaE9hbmVEU0dFckxnVEhuOWtDWlZ2UmlEVlJvSERGTENCVkdrUGlyQy1FUklfaUR3X0tlclFkTmt5UkRGaHRrSg?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T23:23:47+00:00", "published_display": "15 Jul 2026 23:23", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler initiates Veracyte stock with overweight rating", "summary": "Piper Sandler has initiated coverage on Veracyte (NASDAQ:VCYT) with an overweight rating and a price target of $66.00, citing the company's cash-generative diagnostics lab anchored by its Afirma and Decipher Prostate genomic classifiers. These products are expected to drive signi", "url": "https://m.uk.investing.com/news/stock-market-news/piper-sandler-initiates-veracyte-stock-with-overweight-rating-93CH-4771072?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-15T21:40:59", "published_display": "15 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Initiates Veracyte at Overweight With $66 Price Target", "summary": "Piper Sandler has initiated coverage on Veracyte (NASDAQ: VCYT) with an Overweight rating and set a price target of $66. This news comes as Veracyte continues to expand its diagnostic test offerings for various cancers and respiratory diseases. The company was also recently added", "url": "https://www.marketscreener.com/news/piper-sandler-initiates-veracyte-at-overweight-with-66-price-target-ce7f5ed2d989f42c", "source_name": "www.marketscreener.com", "published_at": "2026-07-15T12:40:59", "published_display": "15 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxNT2J0QlhoWjJlTWlMQzFlUTBQdmtBVjFBT3lrRnc1VWhEVWVDMklvRVlFTFVKMHJxMVhuNEQ5blNob3paSC1HZFdWd05Jc2d4NVBaa0JOaU1UWHBBVWNGc2ZIUU0yU1JGb1FhYVRvUUhDa3NyVDJPRTYwdE5nd1dMTGJZOEJVbUx1c1A5NzlzSHVWOFoxa18wQ096RW1MMUpGOXMyaW9lNmIzemR4QzcxQkdtYm5tS3lpcmw5WjZWQno3RURWaXQwWDVZRDhVazY0NWpMQkZMRmtyNndHcUVpSkRsV184SmxFV29HeXRJRGtqaXRFWUNXQjA2SlJqUQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-15T10:59:53+00:00", "published_display": "15 Jul 2026 10:59", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VCYT Initiated Coverage by Piper Sandler -- Rating Overweight", "summary": "Piper Sandler has initiated coverage on Veracyte (VCYT) with an Overweight rating and a price target of $66.00, reflecting a positive outlook on the genomic diagnostics company. However, GuruFocus indicates that VCYT is significantly overvalued by 47.8% compared to its intrinsic ", "url": "https://www.gurufocus.com/news/8959534/vcyt-initiated-coverage-by-piper-sandler-rating-overweight?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T10:12:57", "published_display": "15 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Raises Target Price to $60", "summary": "CCORF has reiterated its Hold rating on Veracyte (VCYT.US) while increasing the target price to $60. This adjustment reflects a continued cautious but not negative outlook on the company's stock performance.", "url": "https://www.moomoo.com/news/post/72937094/ccorf-maintains-veracyte-vcytus-with-hold-rating-raises-target-price", "source_name": "Moomoo", "published_at": "2026-07-15T00:12:57", "published_display": "15 Jul 2026 00:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026", "summary": "Veracyte, Inc. (NASDAQ: VCYT) announced it will release its second quarter 2026 financial results on Wednesday, July 30, 2026, after the close of market. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results and provide a busin", "url": "https://www.moomoo.com/news/post/72736095/press-release-veracyte-to-release-second-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-07-10T11:10:55", "published_display": "10 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Maintains Veracyte(VCYT.US) With Sell Rating, Raises Target Price to $47", "summary": "Morgan Stanley has reiterated its Sell rating on Veracyte (VCYT.US) but decided to raise its target price for the stock to $47. This indicates a continued bearish outlook despite a potentially improved valuation.", "url": "https://www.moomoo.com/news/post/72723676/morgan-stanley-maintains-veracyte-vcytus-with-sell-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-07-10T08:40:06", "published_display": "10 Jul 2026 08:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veracyte-release-second-quarter-2026-200500108.html", "source_name": "Business Wire", "published_at": "2026-07-09T20:05:00+00:00", "published_display": "09 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte sets July 30 call for Q2 2026 results and update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNTnZsZkRCcEZ1dkp4Y0tYeExCZFlDWG1mc0k3YTNXZ2lSZjJXTkswUGo5VWMybWN6YnpyTm5pbXYzZDR2VEJxZUlhX19ROGE2SW9YV0pOMUZBMzYzN3lPeGVhYy0yWlZhT05jRUJRZkdEdldNTGlaX3RvVk1CY2xRZjA0Y2R3R2JISjN1R1V5T0tQN2xkU2l4QXB2a1hBRVMtSU5MWGNGLS1mOXd1R2hWMmMzaTduSVhoRGNfOG5CV1I?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T20:05:00+00:00", "published_display": "09 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VCYT Maintained by Morgan Stanley -- Price Target Raised to $47.", "summary": "Morgan Stanley has maintained an \"underweight\" rating on Veracyte (VCYT) despite raising its price target to $47. The stock is currently trading 53.9% above its GF Value\u2122 of $38.24, indicating it is overvalued. While VCYT has a strong GF Score\u2122 of 75, driven by financial strength", "url": "https://www.gurufocus.com/news/8952082/vcyt-maintained-by-morgan-stanley-price-target-raised-to-4700", "source_name": "GuruFocus", "published_at": "2026-07-09T18:15:46", "published_display": "09 Jul 2026 18:15", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc. Stock 12\u2011Month Price Target Raised to $55.8, Implies 1% Downside", "summary": "Veracyte, Inc.'s average 12-month stock price target has been increased from $54.8 to $55.8 by 10 analysts, with individual forecasts ranging from $42 to $70 per share. Based on the July 8 closing price, this new target suggests a potential 1% downside. The consensus rating from ", "url": "https://www.tradingview.com/news/tradingview:dda31ed86064b:0-veracyte-inc-stock-12-month-price-target-raised-to-55-8-implies-1-downside/", "source_name": "TradingView", "published_at": "2026-07-09T13:15:45", "published_display": "09 Jul 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Veracyte\u2019s (VCYT) Russell Value Index Debut Redefine Its Small-Cap Defensive Narrative?", "summary": "Veracyte (VCYT) was recently included in several Russell value and defensive indices, including the Russell 3000 Value and Russell 2000 Value-Defensive. While these inclusions may attract short-term investor interest and highlight a reclassification of the company, the core inves", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/does-veracytes-vcyt-russell-value-index-debut-redefine-its-s", "source_name": "Simply Wall Street", "published_at": "2026-07-09T06:40:41", "published_display": "09 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Inc updates investors on breast cancer test coverage. Nasdaq-listed diagnostics group builds on genomic portfolio", "summary": "Veracyte Inc is highlighting expanded Medicare coverage for its Prosigna breast cancer assay, a genomic test used to assess recurrence risk. This expansion is crucial for investors as Medicare decisions often influence other payers, potentially increasing test volumes and strengt", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/veracyte-inc-updates-investors-on-breast-cancer-test-coverage/69725654", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T17:39:40", "published_display": "08 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNM0Flb1MzbmVDNGZXRmRZMDA3NW5oRzYzem43T2dzdmtfX3EtZTU0QlplanJOeFBkaDdOaGt5QlVCWWE0VHlQYURpSnBESTZzUDViSEUwempiWjVsbzZVd0pxS2cxYms3Q0RBd0hzWDVYbkRkRHJXVThqR3lCMUVSTVphOWVsNEdLMDBocUo5SU5fUWdMam1YMFdUNVBIWjA?oc=5", "source_name": "Market source", "published_at": "2026-07-08T16:00:04+00:00", "published_display": "08 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Veracyte (VCYT) Fully Valued As Insider Selling And Index Additions Draw Attention?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPQ0E4QW5GTVFKQ3RJR3R0Z195cGJyemNaVU1IcUhDV0FvNTZoeFNZaTRTcTQtanJmaHdKYmhsZkFMX1RIeEFaN3ZUSmdpNGppd2hrZkF1b1dld25XUFppUklJek15dFBFcFBfNUJLaXU3V3VhUlFzLXRxMkYzWTJ6Q3haWmhYM2NNSnZsRy1xX2lCNmhmaFhSUGtkdUVIRTZvMkRtM0oyOTFmT2Jka0Z0U1BDY21qa1diaWcwM25tUldIVVJRYzY5dFI5VUdwWUppV3NrWTFZWkRBUdIB3wFBVV95cUxOamdoSmJWeUpNTEk3NmdvVjdLQ25UNnpWb282RFBLR0ljOHkxWXlGTVdxTFJxVDROMWFqODg1VnBsQXVKaGFqY0Vabm5VY0dZZFZfbHFEUG9ncTBmRkpLVGlxWXp2Y2tVZUx6ZUdOUnZRQVNTTS1RYVd5YkZyV0ExZnVueUNpaVQwY3lNLThQNVZGUzdQenRIY3lkMVBrbXRkdnl0UHB6NGNQUmJsMXhDY3BwVlVIckFCN25IbHJKdEpCakJaLTR4VVFWWlJBYlRNdVFna0tpZ2N0MU1oREJr?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Inc (VCYT) Stock Down 3.2% but Still Overvalued -- GF S", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAJBVV95cUxPcENKT0twTmJfSXI3cWcxY2piTzBsam1sM1dkdG84ZWZETXc0RnZVV0V5VFpyOXV4ZGttMmJiTUMzRnZoWUNibHp2c3B3X2RGNEhOQmV0UXdoZkdMaG1RYXNZQ0dJcEY4SHpjN0VWVXp2SHRSRTlVdUhyU2dMc09WY0NOZ2M2YVZrcjhmV0pWVm8zY05Yb2Y1WlBxQXRQSzhKOTZoUEZlQlM4d3lMckQwaFJpNV9raWdqamdzTjdIUE0yY0s5Mm1YekN1cG5vbzRiWVJXb1ZqcXlQNi1SQ1oyRTYybFFfcmtOaXgzTFk1M19ScG1TYVdzYm5zTTdXNmRzTElWWk9Gdm1UVjhaWktCZjI0cVZZZWVqYmJVZGw1a3M2TWIyV05naThxR21QZl9PbmgwN25xbGNhdU1DdVFQdnNySm9pcXRDeWdXOA?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.", "summary": "Veracyte's Chief Accounting Officer, Jonathan Wygant, sold 24,000 shares for $1.1 million after exercising options, reducing his direct ownership by 34.57%. This transaction, along with a subsequent smaller sale, capitalized on the company's rising stock price driven by strong Q1", "url": "https://finance.yahoo.com/markets/stocks/articles/veracyte-insider-sold-24-000-132501389.html", "source_name": "Market source", "published_at": "2026-07-04T13:40:54", "published_display": "04 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Inc (VCYT) Stock Forecast, Price Targets and Analysts Predictions", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gJBVV95cUxOTXZWU2d4UEJwdVdPeEs2SmttODVOdHdqT0xHckwtNkJla2cxeENNNGVCZEhyRHBzNTFIaHBSRUtNUmZ3YjZNSGRqcVJMWmowajlBN2hZdE91cDNjVjFMTjF1WVFVaUVMeEpNUXNOSXJZUTBXNWlJN0wxRVZJLU5Bd0JvekRHd2hwbFA3WGxWb2ZlWm16SS1RSjZWZUhmZEVyUWxBM2RQUFc3dzNNWnR0VnhwVk00RWxTU2FLUldHdWFuYTlzWTBhRkdSRC1hdWcxWm8zc3hLeGJTb0VxLVpraG9rb1pyZlVCUEE2YmJIODRJcTY1RFMyRlh3QlgzOFF2VUlQOUZnTGFFNWo0R0tQVzVDWmFIQWtBZGZjdlVrTG1RR0YtRzA2ei1VTVNERGVZaFNvZ3JIb2VRZlZ3VkNsUms2LWNBamJmYUtMdnNBMld5eUNHME1KWDJR?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-03T14:14:28+00:00", "published_display": "03 Jul 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Stock Surges 117% in a Year: What's Driving the Rally?", "summary": "Veracyte's stock has surged 117% over the past year, significantly outperforming its industry and the S&P 500, driven by its long-term growth strategy focusing on minimal residual disease testing, international expansion, and new product development. Key catalysts include strong ", "url": "https://www.tradingview.com/news/zacks:74b44e756094b:0-veracyte-stock-surges-117-in-a-year-what-s-driving-the-rally/", "source_name": "TradingView", "published_at": "2026-07-02T18:12:20", "published_display": "02 Jul 2026 18:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 3000 Value Benchmark", "summary": "Veracyte, Inc. (NasdaqGM: VCYT), a global diagnostics company, has been added to the Russell 3000 Value Benchmark. This news follows several other recent additions to various Russell indices, including the Russell 2000 Value, Russell 2000 Value-Defensive, and Russell 3000E Value ", "url": "https://www.marketscreener.com/news/veracyte-inc-nasdaqgm-vcyt-added-to-russell-3000-value-benchmark-ce7f5fdcd08af027", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:39:31", "published_display": "29 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2500 Value Benchmark", "summary": "Veracyte, Inc. (VCYT) has been added to the Russell 2500 Value Benchmark, as well as several other Russell indices including the Russell 2000 Value Benchmark, Russell 2000 Value-Defensive Index, and Russell 3000 Value Benchmark. This inclusion signifies the company's recognition ", "url": "https://www.marketscreener.com/news/veracyte-inc-nasdaqgm-vcyt-added-to-russell-2500-value-benchmark-ce7f5fdfde89f727", "source_name": "marketscreener.com", "published_at": "2026-06-29T19:39:50", "published_display": "29 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VCYT Maintained by Guggenheim -- Price Target Raised to $65", "summary": "Guggenheim maintained a \"Buy\" rating for Veracyte (VCYT) and significantly increased its price target from $45.00 to $65.00, reflecting confidence in the company's future growth. Despite this positive analyst outlook and a strong GF Score\u2122 of 75/100, GuruFocus indicates VCYT is 5", "url": "https://www.gurufocus.com/news/8936431/vcyt-maintained-by-guggenheim-price-target-raised-to-65", "source_name": "GuruFocus", "published_at": "2026-06-29T15:41:50", "published_display": "29 Jun 2026 15:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) Enters Multiple Russell Indexes Is Its Small-Cap Profile Quietly Changing?", "summary": "Veracyte (VCYT) has been added to several Russell indexes, including the Russell 2000 Defensive and Growth-Defensive, which could significantly increase its institutional investor base and trading liquidity. While this inclusion may boost awareness for the company's cancer diagno", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracyte-vcyt-enters-multiple-russell-indexes-is-its-small-c", "source_name": "Simply Wall Street", "published_at": "2026-06-29T14:41:50", "published_display": "29 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Veracyte, Inc. \u2013 NASDAQ:VCYT", "summary": "This page from TradingView displays financial data for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its Price to Book Forward metric. The content lists various financial tools and market data services provided by TradingView and its partners.", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:41:50", "published_display": "29 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2000 Value-Defensive Index", "summary": "Veracyte, Inc. (NasdaqGM: VCYT), a global diagnostics company, has been added to the Russell 2000 Value-Defensive Index. The company provides various diagnostic tests for cancers previously mentioned in the article, such as thyroid cancer and breast cancer, and is developing test", "url": "https://www.marketscreener.com/news/veracyte-inc-nasdaqgm-vcyt-added-to-russell-2000-value-defensive-index-ce7f5fdedb8dfe2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T22:42:00", "published_display": "28 Jun 2026 22:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Veracyte, Inc. \u2013 FWB:12V", "summary": "This article provides financial information for Veracyte, Inc. (FWB:12V) on TradingView, specifically focusing on its enterprise value to revenue forward. It indicates the market status as closed with no trades, and the content primarily consists of navigation and boilerplate inf", "url": "https://www.tradingview.com/symbols/FWB-12V/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T19:39:50", "published_display": "28 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Veracyte, Inc. \u2013 FWB:12V", "summary": "This article provides financial information for Veracyte, Inc. (FWB:12V), specifically focusing on its price-to-sales forward metric. The data is sourced from exchanges and financial data providers, indicating that the market for this stock was closed with no trades recorded at t", "url": "https://www.tradingview.com/symbols/FWB-12V/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:41:50", "published_display": "28 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Veracyte, Inc. \u2013 NASDAQ:VCYT", "summary": "This page provides financial information for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its forward price-to-sales ratio. The content appears to be a financial data page from TradingView, offering an overview of the company's financials for investors and analysts. It", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:40:03", "published_display": "28 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Veracyte, Inc. \u2013 NASDAQ:VCYT", "summary": "This article provides financial information for Veracyte, Inc. (NASDAQ: VCYT), specifically focusing on its enterprise value to EBIT forward. The content is presented within the TradingView platform, which offers various financial tools and data.", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T11:11:16", "published_display": "28 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Veracyte, Inc. \u2013 FWB:12V", "summary": "This article provides financial information for Veracyte, Inc. (FWB:12V), focusing on its forward price-to-earnings ratio. It states that the market is currently closed with no trades recorded and offers data made by humans from various financial services.", "url": "https://www.tradingview.com/symbols/FWB-12V/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:10:34", "published_display": "28 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Veracyte, Inc. \u2013 NASDAQ:VCYT", "summary": "This article provides a brief snapshot of the \"Enterprise value to EBITDA forward\" for Veracyte, Inc. (NASDAQ: VCYT) according to TradingView. It indicates that the market was closed at the time the data was viewed, with no trades recorded. The content is primarily a data point w", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:10:34", "published_display": "27 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) On Pipeline Momentum And A Valuation Question", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-27T09:20:06+00:00", "published_display": "27 Jun 2026 09:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQSXBZeVBPc05Rd0JaczBwTGNaMGN0N2Jnc3F1MktVRzdwLVhPWWFadks0Q2lIYkZJQVM2TFFPZlI1dkZfVkFnTzNReHg0WWdFN0U4d3BwYnZ2cVNDVnlBa0NYektwdHd3RS1JVXZLaDBQNG9wQkw0dzVvWjhkVDdRRENHRl80SlBrS1lZRmY3aVZqRGsxMGs2aURLQU5TdXVOLUQxWWd4Q2VXRThxU0hTUE9wVFdJZmw3Znhsek9lcjMyQUUtaTAwUktR?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc. Actuals & Estimates (NASDAQ:VCYT)", "summary": "This article provides an overview of Veracyte, Inc. (NASDAQ: VCYT) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, such as recent earnings, revenue, net income, and market capitaliza", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T06:10:34", "published_display": "27 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc. Actuals & Estimates (MUN:12V)", "summary": "This article provides an overview of Veracyte, Inc. (MUN:12V) financials, analyst estimates, and key company data. It includes details on past earnings performance, revenue, EBITDA, and analyst price targets, alongside upcoming earnings report dates. The article also addresses fr", "url": "https://www.tradingview.com/symbols/MUN-12V/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T05:39:56", "published_display": "27 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte, Inc. Actuals & Estimates (DUS:12V)", "summary": "This article provides an overview of Veracyte, Inc. (12V) stock details, including financial actuals, analyst estimates, and key performance indicators. It covers income statements, balance sheets, cash flow, and valuation metrics, along with answers to frequently asked questions", "url": "https://www.tradingview.com/symbols/DUS-12V/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T03:11:36", "published_display": "27 Jun 2026 03:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Inc (VCYT) Shares Surge 3.1% -- What GF Score of 75 Tell Investors", "summary": "Veracyte Inc (VCYT) shares surged 3.1% to $58.59 on June 25, 2026, marking a 30.0% appreciation over the last month. Despite a strong GF Score of 75/100, indicating above-average performance, the stock is considered \"Significantly Overvalued\" with a current price considerably abo", "url": "https://www.gurufocus.com/news/8932818/veracyte-inc-vcyt-shares-surge-31-what-gf-score-of-75-tells-investors?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-26T06:10:34", "published_display": "26 Jun 2026 06:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VCYT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Veracyte, Inc. (VCYT) stock, based on analyst ratings and current market performance. It details the company's financial metrics, including recent earnings and revenue, and answers frequently asked questions about its stock pe", "url": "https://www.tradingview.com/symbols/NASDAQ-VCYT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:02", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte stock hits 52-week high at 55.32 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOWGlMZFNxWDBXQV9IOHdDVWJ1cjZyTXlDTEhkbmMxYjJ4ZkRjcFpXSGNKUjd1MjZPN3ZaeWkxWXZmNVlnRk9BbUFvbnlGNnlPdktfREN5S1B2OWtzN1FDeG5ibTdFOTVhd3hMVTRpd0J5UUhOaEFnOUdVaUZLQVdpYzRDQml1YTdkTzZLU1hNVk10UmM5Q2VvbHFTTDBybXl5TFE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) director logs 3,729-share Rule 10b5-1 stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQREhtVGloQk0zRUk5UnpKWXVDUk5USE1fbFRzeWlfbGxicnd4VWxpZGdJdXE5MVhUOFdGLWVZUEVTb01mNWpWc2tXa084RndpbVUtaGljMEdCc1luekVDamFKdFVvY1pTRHl3Tmw3MmNIR2kyZDZwYW9lOW9jcUJFR1JidjRXTloza1RkblF1bVZsaVJWa05OTC10cWZXNWlpbVdPbjUxTDkwQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Top Stock Has Surged. CEO Explains Key To Veracyte's Success.", "summary": "", "url": "https://finance.yahoo.com/m/b5ac36cb-63db-381e-9915-d11885036996/this-top-stock-has-surged..html", "source_name": "Investor's Business Daily", "published_at": "2026-06-18T20:08:24+00:00", "published_display": "18 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] VERACYTE, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQRGxyaWZXdG1RT3ZIMWtOV2R1RGJxcW50dUlYNWg3MFZlMU5JdFFjNVctdDIzVEJtRHZ2bnhRQXM5ZE5Mdk9ZS1NzcXlpcHEyZWRyUWZlVG5HcnBteUFqZDBnbVpzUlgyUnlUWFQwOUh6d2V4RkVnUzJzam9wTGhZUXV1OEpOaERMU01FcTNRamZzdDg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte CEO Explains How It's Blazing A Trail In Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTFJ2RWFyR3RHWTJXaGFUeGxqMEU1Z0pBUDJPUzVEZGNENnFHQmhmeHQxMzc1T25HbXI4UzFORjlYUGFqQ1c1eWJadkh0dXhwbkhISkt2eEVfTzNLRWp6bTR0dmRXT3FuMGhMWngzSTBEVC01MW4xZGdoaFI4TEtwSmN4bWg3Y01PX2lSd3VmT2oxTjZ0REQ0aFhHaUpPOWZ1OGhjaENCZF8?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQY3I3LUtfZ3d5YkxLb1dvVlRrZUkwWmlCdWFGWTFLcDgyTDdlTzd5TjEycHIxYk5RakJreTJHaGFqSHhEckg4N2E5eW90WDYwek9maGFIcFVuS1NSMmRubjlybWVOeUt3UWJ6YUhhNUV3dml5cWFnNy11RTBVNHpEQ21wM25wWUFUQWEwM013QXZCVFlHZGtnVWRLU18yQlpFcEIyVU05YXpSZWNaS1lvMw?oc=5", "source_name": "ChartMill", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Veracyte (VCYT) receives grant of 5,272 restricted stock units", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQV0NudkxndHR1a085TkhTUUFTZl95X1J2aDN3Znd0SGNubUdmdGNrSEJLdjh2eC1VWUdyM2xsc0hUUDlUeWlKdXh6RVdGc1N4di1QUE9zekFQdm1DWG1nWHpacjJmSnBhSlBwQktzR1R1a2tTTm5WRE5FeF9aNW12VE9hdmI0T09ZY2wtZEFReFRESVFPRHF0TVFaTHF6QmFxV3BGUHRLczdHdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPbWlBeXdKT2NQUnFTMTA4c1R2R1NINXpHRDV3X1UycDJtZkRLN2c2Qm02YWhqa3ZtbFNuN00tQ2gzcmdtV1gzcGg5YzExYnYyTjFzU2lhZkc2VUZ3LVdIYTRHODdkNXo4bTcyWENiNTEtc3YzRWV1TW1jNHM5b2J1bVlSYXNFTmxLWmJYQWRNZE5qbDBPRXM1UEZsQjdrYThSU2c?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQdnpWQ0U1R01DZi1neFkwZ054di1RRVZKMjg5dTdBdjQ2ZXRmZ09JT1FCTTJRRU40a3hQRXVRTWFYeXp0QUltN3hOTUhpdjIzYjlndkJlcl84bGZLV1JOVE5IdHVod0lCY0hSdlNDMGhtNE82NDcwWkxGVWM2bGdtWTMyUldCenh1T0JpYjg4VUE?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOd0FtQU5NZFZQS3pHTzBiYTk5MFZqVEE3UHdRWWxZbU5oclN4ZVRYVkVXLWlKdFlvcTBJcGcxXzB0MDZCV1pHZzR5QU9lQnJMWm9xNndCUlF4ZDZCZGhqZEc0a3lFM2hCa0pXWGVDVjZmTVdHUXdSRHB5SDlEYmU1dUN0NW5leXRLbmRLV2tEWDdVdHJDU3daVWpKSng5dTQ4dV9felBBbUh5SnpxU3RNdVg2UVA0b2pWSEZtNUdyZkdQS24tSlNVQlBRY2FoUQ?oc=5", "source_name": "Business Wire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNdnl4SENLa3I4cXVnMmpsXzFjUEduYWVnODllNXI1Y2tzenptbERZQWlvYUZYVUZ6QjBERDBFRkliMmZGbzItWHEzUm9RdWx5RW9GanY2NHBCblVYUXc5R0IxUlhqZGFfOFlvQWpnZXl0aW1sQjhqY1hQbHhOTFdFTU1URmFDRWhDaGcyb0xxRFczeWlXTl9FZk1IcTN6TFNXejBxS3JqSDNaYmJ4OEVZalowQTdQdzd5?oc=5", "source_name": "TradingView", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOeVE4enVvYlZSWFZvNVNuSzhQdXNSQmxLTkJsZlN1YUdLQ09EenhzOVBnM185WGpfVmh3LVg0SVVwS1BjdFR1TDVXX3l4TWtIS09HU3ZzYm8zZHZFNVpLeDBLamUtWXhzNzRmLXc2dkp6UW0wMHJicldlaFNwbV9BVUUtbmprV05sOVlUaDl2YnJwYkFMMW91RnJn?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Veracyte (VCYT) Valuation After Phase III Success For Prosigna And Decipher Cancer Tests", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMnNHZWh0T1RmT0d6VHNrb3JkbWl3UjRqSXR3Q29ENW5CVDhIMG5uOXRoM3kxWEtoa1p3YVhadGtQNURRQjZsMmp5Qy1XbTNkak1KM0tSdzFOSU9tZjdzamZjak03c0dZWWNqX0NIS3FvWm9GWnFZRVBzdlhNZU54bUVmVGhEMW1FWW1hNFZzRXFsTnF0ZnpCMExLQ2dBUVg4V2g5NFp3Zw?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) Q1 2026 Earnings: Revenue Up 21%, EPS Quadruples, Shares Climb 23% - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNRFRnb1lKY3IyUnhQclM3M3pXaFVKSlV0Z1BYMGp1WUdoOVNZdngtNHFkTlhLbkJlSWtMY3pqaXR5U3NYYVdIZXhIazFZNGJBaFR2RlYzR25pS0JnbGlIcV9vVVBuUk1mUzFVejR5WXM0QTR3MTN1d0QxZGw2UG1udVAwN0xSTzRoWlVSbktpXzVraF9yWEJoaU41MDU5SC1GbWRzelJaSldFZw?oc=5", "source_name": "IndexBox", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) Margin Expansion And 166% Earnings Growth Test Premium Valuation Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPb21JY2wweXFMMW9QeWpCdmlJYWJWTFhSYlh1dWcwQXBvSk8yaGVpNURIRTVkLVN4TTFON25ZMHZEOEstOXRPaXRHZEtaeG5PX2FtUGY2T2QyZmZfN3F5bTZoelJpb2w1aWxGLVdaTDZtZ3ZLd0pEM0x5ejFyWVVMemZwZU03UUhRUFByQmZtVWhIQmU3dzZxMkh4RmRJMDl0Vmc?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZ1p4dmlaYVdiQ1oxa2Y0amFTaFBuTnB0Sms2eDhqY3k1TkZ0SDQ1anVreElaME5BSUMxTFc4TEhxeDJSd1ZDN1lQVzJCNTVXbG13Q0RGLTNJR3dMZXJCd2Jlc0ZKZWJjRXgyWXNjc3FhZEdmbWhDQUZpM0tuNFgzMk8xX2p2Y2dSZ0I0ZU9JZlBTVzlmMWFQeV9wbUU?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Veracyte Stock the Right Pick for Your Portfolio Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQWmFfTjk3QTNfY1FEQ1l6ZU5qWHdUU3pZS2JMNzdpSXNSM0pnLVpyZkZkM2YxX1JiclEwampKSGtXM2diWjE4d2JJejhuX2U3LXRmbzJWREc0OE5tdE5PZjNyNmhkdEFmQUJMRjE0aHdXQTNuek5qSDB2WGFjenpwX2VZUEU3eHJlUUJaVDNUZXZUMVVrRFlIYmRFOUpneUk?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQakNsVVNhVFg2NWZjWXNhWkJGdmZjd2Jlb3owUUkzTFJfdGd0em1QRWxPYWRtT3ozMmg4TXA5TjRLZUJEZkJTRTFsRUJGRk5kaE1OcHpkRlVpV2xqVktLdU5SVUliMnhiZjlxNE9lQzN2OFBKeElWRC1tSmdUMjc5Y3AtSTktV0VLbVp6RXJwN1Vidw?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veracyte Taps Kevin Haas To Guide AI Push And Undervalued Shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 105, "total_relevant": 60, "sentiment_summary": {"positive": 23, "negative": 3, "neutral": 34, "score": 58, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 18.15, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 6.05, "count": 11}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 56.97, "latest_week": "2026-07-10", "one_week_move": -0.2, "four_week_move": 20.4, "twelve_week_move": 68.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.381123, "market_dynamics_buy_signal": false, "relative_strength": 29.33288, "fair_value_gap": 79.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.5122, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.2% over one week, +20.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 14}, {"label": "Market source", "count": 10}, {"label": "GuruFocus", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 60}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 11}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "60", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.2% over one week, +20.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "A Look at Veracyte Inc (VCYT) After 5.1% Gain -- GF Value $38.30 vs Price $59.51"}], "updated_at": "2026-07-16T12:57:14.227247+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}